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We have previously reported that the negative signaling regulator Similar Expression to FGF (hSef) is downregulated in prostate
cancer and its loss is associated with clinical metastasis. Here, we explored the mechanistic basis of this finding. We first
confirmed our clinical observation by testing hSef manipulation in an in vivo metastasis model. hSef stable expressing cells
(PC3M-hSef) or empty vector controls (PC3M-EV) were injected subcutaneously into the lateral thoracic walls of NOD-SCID
gamma mice and lungs were harvested at autopsy. In this model, 6/7 PC3M-EV xenografts had definitive lung micro-metastasis
whilst only 1/6 PC3M-hSef xenografts exhibited metastasis recapitulating the clinical scenario (p50.03). Gene expression stud-
ies revealed key perturbations in genes involved in cell motility and epithelial to mesenchymal transition (EMT) along with altera-
tions in cognate signaling pathways. These results were validated in an EMT specific PCR array whereby hSef over-expression
and silencing reciprocally altered E-Cadherin expression (p5<0.001) amongst other EMT markers. Immunohistochemistry of
excised tumors from the xenografts also confirmed the effect of hSef in suppressing E-Cadherin expression at the protein level.
Phosphokinase arrays further demonstrated a role for hSef in attenuating signaling of not only ERK-MAPK but also the JNK and p38
pathways as well. Taken together, these data suggest evidence that loss of hSef may be a critical event facilitating tumor dissemi-
nation of prostate cancer through alteration of EMT. Detection of downregulated hSef, along with other negative regulators, may
therefore be a useful biomarker heralding a transition to a metastatic phenotype and warrants further exploration in this context.
Aberrant intracellular signaling is considered one of the hall-
marks of cancer.1,2 Intracellular signaling however is subject
to different levels of regulation that serve to attenuate the
eventual impact of stimulation.3 Negative signaling regulators
(NSR) are feedback-induced mechanisms that are innate to
the cell. There is now emerging evidence that NSR are
themselves altered in the transition from benign to malignant
cells.4 Similar Expression to FGF (Sef) has been particularly
well characterized as a tumor suppressor in a diverse range
of cancers.5
The ﬁrst of the Sef proteins to be discovered was zebraﬁsh
Sef (zSef), which consists of a putative transmembrane domain
with a tyrosine phosphorylation site juxtaposed to the receptor
(type I transmembrane receptor).6 Genomic sequence analysis
revealed a 15–20% homology to the intracellular domain of
the interleukin-17 receptor (IL17R),6,7 giving it the alternative
name of interleukin-17 receptor D (IL17RD). Sef has since
been identiﬁed in other vertebrates including chick (cSef),
mouse (mSef) and human (hSef).8–11 The mechanism by
which Sef regulates receptor tyrosine kinase (RTK) signaling
remains contentious and is likely to be cell type speciﬁc. Tsang
et al. in co-immunoprecipitation experiments have shown that
zSef interacts at the level of the FGF receptor.6 Kovalenko
et al. have further shown that overexpression of mSef inhibited
phosphorylation of FGFR1 and the adaptor protein FRS2.9 Sef
interaction at the level of the receptor has also been shown in
PC-12 rat medulla cells.12 Consistent with these ﬁndings, work
in our unit in human prostate cancer has shown that hSef is
likely to act at or above the level of Ras.13,14 Other groups
however have proposed that hSef may function further down-
stream and potentially act as a spatial regulator of ERK
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signaling.15 Despite the uncertainly on the site of hSef action,
it is clear that hSef is an important regulator of diverse signal-
ing pathways.16 This key regulatory role has raised an impor-
tant question on its potential role in cancer development and
progression.
A number of NSR have been shown to be altered in can-
cers and loss of expression has been consistently associated
with a more aggressive tumor phenotype.3 hSef in particular
has been investigated in a number of tumor types including
endometrial, ovarian, breast and thyroid and shown to be
downregulated in cancer.5,14,16 In prostate cancer, our group
was the ﬁrst to demonstrate loss of hSef transcript expression
in metastatic clinical tumors.17 This observation was further
conﬁrmed at the protein level in an expanded study.13 In a
series of 141 cancers, hSef protein was weak or absent in
46% of biopsies from men with bone metastasis but in only
17% of men without metastasis.13 This data raises the possi-
bility that hSef may have an important role as a gatekeeper
in the development of disseminated disease. In this study, we
explored our clinical observation by modeling the effect of
hSef manipulation in vivo and in vitro. Speciﬁcally, our objec-
tive was to understand the mechanism by which hSef might
facilitate prostate cancer metastasis.
Material and Methods
Cell lines and xenograft experiments
PC3 cells were obtained from the American Type Culture
Collection and the PC3M cell line (a metastatic derivative of
PC3) was a gift from Professor H. Leung (Glasgow). PC3M
cells were seeded into 90 mm tissue culture dishes and trans-
fected with pCDNA3.1-Sef-Myc (gift from Professor Z
Chang, Tsinghua University, China) or pcDNA3.1 (Invitro-
gen, UK) using Lipofectamine 2000 (Invitrogen, UK) before
being placed under G418-sulphate selection for 14–20 days.
Individual colonies were removed by trypsinisation and
expanded. Cells were maintained in RPMI-1640 media (Sig-
ma, UK) containing 10% foetal calf serum, termed full medi-
um (FM). For xenograft studies two million PC3M-hSef or
control cells (suspended in 50 ll of PBS and 50 ll of Matri-
gel solution) were injected subcutaneously into the lateral
thoracic walls of NOD-SCID gamma mice (Charles River,
UK; 10 each with PC3M-hSef and PC3M-EV cells). The
tumor size at the injection site was measured weekly using
calipers and was calculated using the formula: volume 5
(p/6)/abc or (p/6)/abb (if only 2 diameters are available) and
a,b,c are the orthogonal axis of the tumor. At autopsy (typi-
cally weeks 4–7), the primary tumor and lungs were har-
vested. In vivo experiments were reviewed and approved by
the institutional animal welfare committee and performed
according to the UKCCCR guidelines.
H&E and immunohistochemistry
Harvested tissue was ﬁxed in 10% Neutral Buffered Formalin
for 24 hrs and stored in 70% ETOH. H&E staining on the
harvested lungs were performed and mounted on slides
before image capture and storage. Immunohistochemistry
against E-Cadherin and hSef was performed on the harvested
xenograft tissue from the primary injection site using the
BondMax Autostainer (Leica, UK). Brieﬂy, the process
involved the retrieval of antigen by heat retrieval (1008C) fol-
lowed by incubation with anti E-Cadherin antibody (Novo-
castra, UK) or anti hSef antibody (Sigma, UK) at a dilution
of 1:25 or 1:500 at room temperature for 15 min, respective-
ly. The samples were then incubated in a polymer secondary
system (Leica) and developed with Diaminobenzidine using
copper enhancement. All histopathology sections were scored
by an experienced uropathologist (AW). The presence of
metastasis was deﬁned as >2 separate sites involved with
tumor cells or a single area with >5 tumor cells.
Illumina microarray, EMT specific PCR array
and real-time PCR
Total RNA was isolated from PC3M-hSef and PC3M-EV cells
maintained in FM using the RNeasy Mini Kit (Qiagen, UK).
Microarray experiments were performed using the HT12v4
beadchip (Illumina, UK). Gene ontology analysis on the resul-
tant data was performed using Ingenuity Pathway Analysis
(Qiagen, UK) and MetaCoreTM (Thomson Reuters, UK) soft-
ware with all genes that were differentially expressed by 2 fold
(up or downregulated) with p< 0.01 considered for analysis.
Changes in expression of EMT related genes in PC3M-Sef and
PC3M-EV cells were investigated using the EMT speciﬁc RT2
Proﬁler PCR Array (Qiagen, UK). In knockdown experiments
PC3 cells were grown in FM for 24 hrs before being transfected
with 33 nM of hSef siRNA or Scramble (Scr) control (Dharma-
con, UK). ERK-MAPK inhibition experiments were performed
using 30 lM of ERK inhibitor FR180204 (Sigma, UK) sus-
pended in FM. Real-time PCR analysis were performed using
primers obtained from the TaqManV
R
Gene Expression Assay
What’s new?
The loss of negative signaling regulators may be implicated in prostate cancer metastasis, but the underlying mechanisms
remain unclear. Here, by using a combination of xenograft, gene expression microarray, phosphokinase array and quantitative
PCR techniques, the authors provide first evidence that the negative regulator hSef plays a key role in regulating epithelial to
mesenchymal transition (EMT) in prostate cancer, which in turn results in changes in the metastatic ability of tumor cells. The
results support the notion that the expression levels of hSef and other negative signaling regulators may be key biomarkers
for the identification of triggers for metastasis.
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catalogue (Applied Biosystems, UK) or using in-house designed
primers with SYBR green mastermix (Roche, UK). The
sequence of our in-house primers was as follows: hSef(F)
CTGCTCCGTCTTCTTTACGG, hSef(R) GTGATGTTGTAC
AGCCCACTGTT, E-Cadherin(F) AGCGTGTGTGACTGT
GAAGG, E-Cadherin(R) CAGCAAGAGCAGCAGAATCA,
GAPDH(F) GAAGGTGAAGGTCGGAGTC, GAPDH(R) TGG
AAGATGGTGATGGGATT. All experiments were assayed on
the LightcyclerV
R
480 Real-time PCR machine (Roche, UK) using
GAPDH as a housekeeping reference.
Western blotting and phosphokinase arrays
Cell lysates of hSef knockdown (or Scr control) PC3 cells
were obtained at various time-points post stimulation with
FM. Cells were lysed directly using SDS sample buffer con-
taining 10% b-mercaptoethanol. Samples were denatured and
separated using SDS–PAGE. Proteins were transferred onto a
PVDF membrane and probed with primary antibodies
against total or phosphorylated ERK1 and ERK2 (Cell Signal-
ing Technologies, UK) followed by incubation in the appro-
priate horseradish peroxidase-conjugated anti-rabbit or anti-
goat secondary antibodies (Amersham Life Science). Separate
aliquots of these preparations were used in the R&D Systems
(UK) Proteome Proﬁler Phosphokinase antibody array
(PKA). Changes in phosphorylation were calculated against
pre-stimulation samples using image quantiﬁcation as per the
manufacturer’s instructions.
Statistical analysis
Data was analysed using the student’s t test for unpaired
samples or Fisher’s exact test for categorical data. p< 0.05
was considered statistically signiﬁcant.
Results
hSef inhibits tumor dissemination in an in vivo metastatic
model
Previously, we have demonstrated that hSef expression is
closely linked with tumor aggressiveness, with reduced
expression being a feature of high-grade and metastatic clini-
cal prostate cancer.13 To corroborate this ﬁnding in vivo, a
xenograft model was adapted from a previously reported pro-
tocol for prostate cancer lung metastasis using PC3M.18 This
cell line is known to have very low levels of endogenous
hSef.17 PC3M-EV and PC3M-Sef cells were used to produce
lateral thoracic wall tumors in immune-deﬁcient mice (Fig.
1a). The generated tumors exhibited signiﬁcantly different
dynamics with PC3M-Sef tumors growing at a much slower
rate compared to PC3M-EV tumors (Fig. 1b). Harvested lung
tissue was assessed for the presence of lung metastasis follow-
ing autopsy. In total, only two out of ten xenografts injected
with PC3M-hSef had deﬁnitive evidence of lung metastasis
(Fig. 1c). In contrast, PC3M-EV readily metastasized to the
lungs with nine out of ten xenografts showing evidence of
large pulmonary deposits (p< 0.01). In PC3M-hSef bearing
mice, not only were there fewer metastatic deposits, but those
cells that did metastasize produced very small lesions in com-
parison to PC3M-EV (Fig. 1c). We further compared meta-
static incidence matched for ﬁnal tumor volume. In this
analysis, 6/7 PC3M-EV xenografts (mean volume 1.25 cm3)
had lung micro-metastasis whilst only 1/6 PC3M-hSef (mean
volume 1.27cm3) exhibited metastasis (p5 0.03). Collectively,
these ﬁndings recapitulate the observations from our clinical
studies of a role for hSef in inﬂuencing tumor metastasis.13
This effect appears to be independent of primary tumor size.
hSef alters the expression of genes involved in EMT
Given our ﬁnding that hSef inﬂuences the metastatic ability
of prostate cancer cells in vivo, we next sought to investigate
the possible biological mechanisms by which this effect is
permeated. For this, RNA extracted from PC3M-hSef and
PC3M-EV cells following 24 hrs’ stimulation with FM was
interrogated for comparative gene expression using the Illu-
mina HT12v4 beadchip. Gene network analysis revealed that
the top network of genes most inﬂuenced by hSef were those
involved in cellular movement, cancer, cellular growth and
proliferation. Gene ontology analysis was reﬁned further by
enriching according to biological functions. This revealed
that genes involved in cell adhesion, Extra Cellular Matrix
remodeling and Epithelial to Mesenchymal Transition (EMT)
appeared to be the most biologically altered by hSef.
We next pursued this observation by investigating the effect
of hSef using an EMT gene speciﬁc PCR array. In this assay,
hSef overexpression with FM stimulation resulted in a signiﬁ-
cant upregulation of E-Cadherin expression, a key adhesion
molecule involved in EMT (Fig. 2a). In addition, a number of
genes involved in upregulating EMT were concomitantly sup-
pressed including SIP1, ZEB2, WNT5B, ITGA5, IGFBP4,
STEAP1 and SNAI2 (Fig. 2a). The most markedly downregu-
lated gene was Versican, a chondroitin sulphate proteoglycan
known to increase cell migration, growth and metastasis.19 We
next tested the converse effect of hSef suppression on E-
Cadherin using targeted siRNA in PC3 cells (known to express
high levels of endogenous hSef17 (Fig. 2b). qPCR analysis
revealed that the knock-down of hSef in PC3 cells stimulated
with FM resulted in a signiﬁcant decrease (>80%) in the
expression levels of E-Cadherin compared to non-targeting
controls (Fig. 2c). Given the central role of hSef in attenuating
the ERK-MAPK pathway, we next investigated whether hSef
alters the expression of E-Cadherin through this pathway. To
test this, the above experiment using PC3 control and hSef
knockdown cells were repeated using an ERK inhibitor
(FR18020). Our results revealed that ERK inhibition signiﬁ-
cantly reduced the downregulation of E-Cadherin expression
that was seen as a result of hSef knockdown (Fig. 2d). Collec-
tively, our results suggest that hSef inﬂuences E-Cadherin
expression through modulation of the ERK-MAPK pathway.
To corroborate our observation that hSef inﬂuences E-
Cadherin expression, histological sections obtained from the
primary xenografts tumor sites were subjected to immunohis-
tochemistry for E-Cadherin protein. On histological features
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alone PC3M-hSef tumors appeared more densely packed
compared to PC3M-EV (Fig. 2e). Concomitantly, PC3M-hSef
expressed markedly higher levels of E-Cadherin compared to
EV tumors (Fig. 2f).
hSef expression simultaneously attenuates ERK, p38 and
JNK pathways
The role of hSef in modulating the ERK-MAPK pathway is
well described7,9,12–15 and our ﬁndings adds further weight to
Figure 1. hSef overexpression reduces the metastatic ability of prostate cancer cells in vivo. (a) Site of hSef overexpressing PC3M cells
(PC3M-hSef) or control (PC3M-EV) cells injected subcutaneously into the lateral thoracic walls of NOD-SCID gamma (NSG) mice. (b) Serial
measurement of tumor volumes at the primary injection site. PC3M-hSef cells grew slower and formed smaller tumors compared to PC3M-
EV cells. Error bars refer to the range of tumor sizes at each time point and represent 10 animals at each time point (c) Representative
images of the lung sections of xenografts demonstrating the sites of metastasis with prostate cancer cells. Note that PC3M-hSef bearing
mice produced significantly smaller metastatic deposits compared to their EV counterparts. (**p5<0.01, ***p5<0.001).
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the importance of this pathway in attenuating the expression
of E-Cadherin, a key adhesion protein involved in the EMT
process. It is currently not known however, whether hSef has
any effect on other intracellular signaling pathways that are
involved in mediating EMT such as p38 and JNK.20 To
investigate this, hSef expression was suppressed using siRNA
(or Scr controls) in PC3 cells and stimulated with FM before
being tested in a phosphokinase array (PKA). We re-conﬁrm
the robustness of our model system by testing for ERK phos-
phorylation using western blot. As expected, hSef knockdown
Figure 2. hSef attenuates the expression of EMT genes. (a) EMT specific RT2 Profiler PCR array revealed that a number of genes involved in
the process of EMT were de-regulated as a result of hSef over-expression. The gene most upregulated was E-Cadherin. One of three repli-
cate experiments is shown. (b) siRNA against hSef was performed using PC3 prostate cancer cells with a >80% knock-down efficiency. (c)
hSef knockdown with FM stimulation resulted in a marked downregulation of E-Cadherin expression (>80%). Error bars represent the mean
of three experiments done in triplicate. (d) The experiment was repeated using an ERK-inhibitor (FR18020) which revealed that ERK signal-
ing blockade significantly reduced the downregulation of E-Cadherin expression that was seen as a result of hSef knockdown. Error bars
represent the mean of the experiment performed in triplicate. (e) H&E sections from the primary xenograft tumor injection sites. PC3M-EV
cells were histologically more segregated in comparison with the hSef over-expressing PC3M cells. (f) Immunohistochemistry against hSef
protein confirms high expression in PC3M-Sef but not in PC3M-EV tumors. E-Cadherin protein immunohistochemical expression was noted
to be absent or very low in PC3M-EV tumors but increased in hSef over-expressing xenografts. Representative tumors are shown for both
E and F. (*p5<0.05, ***p5<0.001).
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resulted in a signiﬁcant enhancement in both intensity and
duration of ERK phosphorylation (Fig. 3a). This was
matched in the PKA panel whereby hSef silencing resulted in
a signiﬁcant increase in the phosphorylation of ERK 1/2
compared to scramble transfected cells in response to FM
stimulation particularly at the 15 and 60-min time-points
(Fig. 3b). Across the rest of the panel, hSef silencing also
resulted in enhanced phosphorylation of p38 (Fig. 3c) with a
similar trend also seen for JNK (Fig. 3d). These results sug-
gest that hSef simultaneously attenuates an array of intracel-
lular signaling pathways, which are known to have a role in
mediating EMT.
Discussion
Metastasis is a critical and devastating step in prostate cancer
progression.21 The biological mechanisms that lead to pros-
tate cancer metastasis remain poorly understood but a com-
mon ﬁnal pathway is through activation of EMT.22 In
addition to facilitating tumor dissemination, EMT has also
been implicated in resistance to radiotherapy and chemotoxic
agents.23,24 EMT is therefore an important target when con-
sidering novel agents in cancer therapy.
There is good evidence to implicate the loss of NSR in
prostate cancer metastasis.4 hSef in particular, has been consis-
tently shown to be downregulated in advanced and metastatic
tumors.5,17 To date however, the functional consequences of
this downregulation were thought to be primarily due to
changes in cellular growth and proliferation. In this study, we
have demonstrated that altering hSef expression has a direct
effect in modulating EMT. This is consistent with previous
reports of a similar role for other NSR. RKIP1 overexpression,
for instance, has been shown to suppress EMT in naso-
pharyngeal cancers.25 Members of the Sprouty family are
known to repress TGFb-induced EMT in the context of cata-
ract development.26 Recent work from the same group has
since shown a similar role for Spreds 1–3 and Sef in the same
context.27 Furthermore, He et al.28 recently revealed that hSef
plays a role in the negative regulation of EMT in a b-catenin
dependent manner in breast cancer cells. These data corrobo-
rate and support our own ﬁndings in this study on the role of
hSef in attenuating EMT in prostate cancer.
The exact mechanism by which hSef inﬂuences EMT in
prostate cancer is currently unknown. Recently, hSef overex-
pression was found to prevent the downregulation of E-
Cadherin in a normal breast epithelial cell line that was
forced to undergo EMT in a TGFb dependent manner.28 As
TGFb induced EMT occurs through canonical and nonca-
nonical pathways,29 it is conceivable that hSef modulates
EMT by attenuating the various MAPK signaling pathways
as was seen in the present study. Speciﬁcally, in the context
of E-Cadherin it appears that hSef inﬂuences its expression,
at least in part, through the attenuation of the ERK-MAPK
Figure 3. hSef simultaneously attenuates the ERK, p38 and JNK MAPK signaling pathways in prostate cancer cells. (a) Western blot on hSef
knockdown PC3 cells resulted in an increase in phosphorylation of ERK 1/2 (p-ERK) in response to growth factor rich media stimulation
(FM). One of three replicate experiments is shown. (b) hSef knockdown in PC3 cells stimulated with FM also resulted in an increase in the
phosphorylation of ERK 1/2 MAPK on the PKA assay, recapitulating the results from the western blot shown in A. (c) hSef knockdown also
resulted in an increase in phosphorylation of p38 and (d) increased phosphorylation of JNK. One representative of 2 repeat phosphokinase
array experiments is shown. (*p5<0.05, **p5<0.01, ***p5<0.001).
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pathway. Further studies are required to elucidate the exact
mechanism by which hSef inﬂuences EMT in prostate cancer.
In conclusion, we have demonstrated here ﬁrst evidence
that hSef has a key role in regulating EMT in prostate cancer,
which in turn results in changes in the metastatic ability of
tumor cells. This we have now demonstrated in vitro, in vivo
and in clinical studies. These ﬁndings support the general
notion that hSef and other NSR are important tumor sup-
pressors and a loss of expression leads to a metastatic pheno-
type. Taken together, this argues strongly for the possibility
that the expression levels of hSef and other NSR may be key
biomarkers in identifying triggers for metastasis. In addition,
while the notion of targeting loss of expression proteins is
challenging in terms of therapy, overcoming this paradigm
may provide a new class of therapeutic agents, which can
inhibit tumor dissemination and therefore alter the natural
history of the disease.
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